With WCG’s Endpoint Adjudication Committee (EAC) process, we help the biopharma and device industry to lower the risk of variation in important clinical trial outcome events for submission to regulatory agencies.
Our independent adjudication process enhances safety and efficacy in:
Endpoint Adjudication is a critical aspect of a clinical trial as it helps to lower the risk of variation in important clinical trial outcome events for submission to regulatory agencies. From a global perspective, our Endpoint Adjudication service reduces regional variation in outcome reporting and also serves as a quality control check that uses clinical expert review of principal investigator reporting.
Our Endpoint Adjudication Committees are run by a dedicated team of more than 550 medical, statistical, and safety experts who serve as advisors to clinical trial sponsors, academic experts and regulatory agencies. Their main objective is to reduce the variation in important clinical trial events and ultimately mitigate risk and enhance patient safety in clinical trials.
Sponsors who tap into WCG’s network committee:
Interested to learn more? Schedule a consultation with our experts.
Our proprietary AIMS™ technology is purpose-built for committee management. AIMS™ streamlines processes and diminishes administrative burden, allowing committee members to focus on providing their expert assessments. AIMS™ makes online data review and communication as seamless as possible for committee members, sponsors and other personnel spanning the globe.
We administer the system, while managing data and content, to ensure appropriate review and a complete audit trail for all activity. With the power of AIMS™ and the support of our experienced project oversight, we make committee member recruitment, training, invoicing, communication, and overall committee management as straightforward, efficient and constructive as possible.
Enhancing trial integrity and reducing variation in important clinical trial events are critical components of risk mitigation and patient safety. To improve the quality and effectiveness of clinical trial data requires regulatory expertise; through ACI’s endpoint adjudication and data monitoring safety committees, sponsors and CROs can benefit from a network of 550 members to enable more informed decision-making. Their expert reviews deliver reliable, trusted information to support critical decisions around clinical development programs.
To explore the potential benefits of endpoint adjudication, we suggest an exploratory conversation to assess your plans and how our capabilities can be leveraged to assist. To start, simply fill out the form.